Friday, November 10, 2023 11:33:40 AM
They are offering GV instead of V for Part D plans, which is clearly patent infringement for the R-IT indication - problem is the formularies for 2024 and prior years simply list it under "LIPID/CHOLESTEROL LOWERING AGENTS" - I don't think it's ever been on their list as "CARDIOVASCULAR AGENTS", so proving R-IT infringement would be difficult. GV is listed under "LIPID......" and it's T4, $200/mo copay - but GV was not available on their 2023 formulary, now it is - since TG lowering drugs have lost a lot of coverage (no generic Lovaza) Cigna adding GV for 2024 can only mean it's for R-IT.
As far as delisting and going to the OTC or pinks market, yeah it's not the end of the world but some brokers won't let clients buy penny stocks on those exchanges (TDA will but it costs you $7/trade). The problem with OTC stocks is they have very limited SEC reporting requirements, next to nothing, so you have no idea what the balance sheet looks like, what they're spending on SG&A, what COGS is - nada. There *are* some foreign stocks with large market caps on the OTC market - all of these have MC's in the billions, with Tencent's MC being a whopping:$375B USD:
Luckin Coffee Inc. (LKNCY), the Chinese coffee chain
Tencent Holdings LTD (TCEHY), the Chinese multimedia company
DiDi Global Inc. (DIDIY), the Chinese mobility technology platform
SAP SE (SAPGF), the German software company
There's no reason for companies that big to be on the OTC market except they want to avoid SEC scrutiny and filing 10-Q's or annual reports - quite common for Chinese stocks.
How exactly do you think AMRN can regain compliance with NASDAQ listing requirements wrt to trading under $1 for a period of time? There is zero indication the market will push the pps above $1, so a RS is close to inevitable - and as I mentioned a RS usually wipes out long time owners, cost basis goes so high. I once owned the shipper DRYS, which did eight ]reverse stock splits between March 2016 and July 2017 (it was a racket run by the DRYS CEO and a VC firm, Kalani Investments to steal the company from investors, to this day still can't believe it was legal, or rather that no one got prosecuted for securities fraud) - before my position was reduced to zero after one of those RS's, my basis had soared to $72k/shr!
Citigroup probably had the most famous (or infamous) RS of all time - it was widely held and had a huge MC - if you had the misfortune of buying it between 2001 and 2007 around $40-$50 or more you got wiped out - a May 2011 1:10 RS pushed the pps up from $4 to $40, but you now had 1/10th the number of shrs - a $10k investment at $50/shr (200 shrs) turned into 20 shrs at $40/shr worth a piddling $800 today - that other money ($9200) is gone forever - there are very few ARNA's out there that eventually thrived after a RS. I found an old study that tracked stocks with RS's from 1995 to 2011 and it showed only 29% survived at least 5 yrs post-RS, avg. survival time for those that went under was < 3 yrs. But that's ancient data, don't know what the numbers are if you include RS's up to 2022, but I seriously doubt the numbers got any better, probably got worse because SPACs and reverse mergers didn't exist before 2011 - a large number of them are just scams. If you own a stock that undergoes a RS you can pretty much kiss your money goodbye - I have two stocks that had big RS's to stay listed, one was a 1:20 RS, the other a massive 1:400 RS - I'm down 99% in both, should just dump them to clean up my "balance sheet" because neither one is going to survive, one is already just an empty shell company, but I hang onto them as a reminder to never invest more than a few grand in a spec stock.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM